Table: q1_q4_2022_prescription_drug_wac_increases , manufacturer_name like B*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264959420	0.4% LIDOCAINE HCL AND 5% DEXTROSE INJECTION, Injectable, 400mg/100mL, 250ml bag, 24 bags per case	08/01/2022	38.25	175.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264959410	0.4% LIDOCAINE HCL AND 5% DEXTROSE INJECTION, Injectable, 400mg/100mL, 500mL bag, 24 bags per case	08/01/2022	13.61	200.88	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264959820	0.8% LIDOCAINE HCL AND DEXTROSE INJECTION, Injectable, 800mg/100mL, 250mL bag, 24 bags per case	08/01/2022	12.39	182.64	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264180032	0.9% SODIUM CHLORIDE INJECTION USP, Injectable, 900 mg/mL, 100mL bag, 64 bags per case	08/01/2022	13.44	158.72	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264180036	0.9% SODIUM CHLORIDE INJECTION USP, Injectable, 900 mg/mL, 25mL bag, 116 bags per case	08/01/2022	46.77	291.16	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264180031	0.9% SODIUM CHLORIDE INJECTION USP, Injectable, 900 mg/mL, 50mL bag, 84 bags per case	08/01/2022	17.64	208.32	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264762320	10% DEXTROSE AND 0.20% SODIUM CHLORIDE INJECTION USP Injectable, 10gm/100mL Dextrose; 200mg/100mL Sodium Chloride, 250mL bag, 24 bags per case	08/01/2022	6.92	81.84	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264762200	10% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP, Injectable, 10gm/100mL Dextrose; 450mg/100mL Sodium Chloride, 1000mL bag, 12 bags per case	08/01/2022	8.12	95.52	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264752000	10% DEXTROSE INJECTION USP, Injectable, 10gm/100mL, 1000mL bag, 12 bags per case	08/01/2022	28.94	66.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264752020	10% DEXTROSE INJECTION USP, Injectable, 10gm/100mL, 250mL bag, 24 bags per case	08/01/2022	37.07	88.08	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264752010	10% DEXTROSE INJECTION USP, Injectable, 10gm/100mL, 500mL bag, 24 bags per case	08/01/2022	30.09	96.72	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264761620	5% DEXTROSE AND 0.20% SODIUM CHLORIDE INJECTION USP, Injectable, 5gm/100mL Dextrose; 220mg/100mL Sodium Chloride, 250mL bag, 24 bags per case	08/01/2022	39.23	90.24	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264751020	5% DEXTROSE INJECTION USP, Injectable, 5gm/100mL, 250mL bag, 24 bags per case	08/01/2022	6.41	74.88	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264751010	5% DEXTROSE INJECTION USP, Injectable, 5gm/100mL, 500mL bag, 24 bags per case	08/01/2022	6.85	81.36	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264310311	CEFAZOLIN 1G 50ML ISO-OSMOTIC DEXINJ DUPLEX DRUG DEL SYSTEM, Eq 1gm base/vial, 50mL bag, 24 bags per case	08/01/2022	19.68	292.08	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264310511	CEFAZOLIN FOR INJECTION USP AND DEXTROSE INJECTION USP IN THE, Eq 2gm base/vial, 50mL bag, 24 bags per case	08/01/2022	30.75	337.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264319311	CEFEPIME FOR INJECTION USP AND DEXTROSE INJECTION USP DUPLEX, Injectable, Eq 1gm base/vial, 50mL bag, 24 bags per case	08/01/2022	40.92	449.52	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264319511	CEFEPIME FOR INJECTION USP AND DEXTROSE INJECTION USP DUPLEX, Injectable, Eq 2gm base/vial, 50mL bag, 24 bags per case	08/01/2022	98.88	681.84	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264312311	CEFOXITIN FOR INJECTION IN THE DUPLEX CONTAINER, Injectable, Eq 1gm base/vial, 50mL bag, 24 bags per case	08/01/2022	28.43	420.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264312511	CEFOXITIN FOR INJECTION IN THE DUPLEX CONTAINER, Injectable, Eq 2gm base/vial, 50mL bag, 24 bags per case	08/01/2022	50.73	752.16	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264314511	CEFTAZIDIME FOR INJECTION USP AND DEXTROSE INJECTION USP DUPLEX, Injectable, Eq 2gm base/vial, 50mL bag, 24 bags per case	08/01/2022	38.15	565.92	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264315311	CEFTRIAXONE FOR INJECTION AND DEXTROSE INJECTION IN DUPLEX, Injectable, Eq 1gm base/vial, 50mL bag, 24 bags per case	08/01/2022	29.64	438.24	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264957710	HEPARIN IN DEXTROSE INJECTION, Injectable, 4,000 Units/100mL, 500mL bag, 24 bags per case	08/01/2022	25.56	379.68	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264956710	HEPARIN SODIUM IN 5% DEXTROSE INJECTION (500 U/ML), Injectable, 5,000 Units/100mL, 500mL bag, 24 bags per case	08/01/2022	21.72	321.36	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264318311	MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER 0.5G, Powder, 500mg/vial, 50mL bag, 24 bags per case	08/01/2022	42.62	468.24	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264318511	MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER 1 G, Powder, 1gm/vial, 50mL bag, 24 bags per case	08/01/2022	103.73	699.60	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264553532	METRO IV (METRONIDAZOLE INJECTION 0.5%), Injectable, 500mg/100mL, 100mL bag, 24 bags per case	08/01/2022	5.30	76.80	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264446030	NUTRILIPID 20%, Injectable, 20%, 250mL bag, 12 bags per case	08/01/2022	27.35	282.72	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264446010	NUTRILIPID 20%, Injectable, 20%, 500mL bag, 12 bags per case	08/01/2022	34.61	358.08	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264738860	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, Solution, 900mg/100mL, 3000mL, 4 bags per case	08/01/2022	4.54	66.96	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264738550	STERILE WATER FOR INJECTION USP, Liquid, 100%, 2000mL bag, 4 bags per case	08/01/2022	12.34	44.40	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264738560	STERILE WATER FOR INJECTION USP, Liquid, 100%, 3000mL bag, 4 bags per case	08/01/2022	12.57	52.16	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264785000	STERILE WATER FOR INJECTION USP, Liquid, 100%1000mL, 1000mL bag, 12 bags per case	08/01/2022	6.19	47.88	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264738650	STERILE WATER FOR IRRIGATION USP, Liquid, 100%, 2000mL bag, 4 bags per case	08/01/2022	13.93	54.76	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264738660	STERILE WATER FOR IRRIGATION USP, Liquid, 100%, 3000mL bag, 4 bags per case	08/01/2022	4.74	70.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208035310	ALREX® (loteprednol etabonate ophthalmic suspension 0.2%), 10mL	01/01/2022	30.13	532.30	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208035305	ALREX® (loteprednol etabonate ophthalmic suspension 0.2%), 5mL	01/01/2022	15.07	266.16	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208062901	BEPREVE™ Ophthalmic Solution USP, 1.5%, 10mL	01/01/2022	27.72	489.82	01/13/2025	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208062902	BEPREVE™ Ophthalmic Solution USP, 1.5%, 5mL	01/01/2022	14.50	256.11	01/13/2025	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208044605	BESIVANCE® (besifloxacin ophthalmic suspension 0.6%), 5mL	01/01/2022	11.42	201.71	01/09/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208080060	LACRISERT® (hydroxypropyl cellulose ophthalmic insert), 5mg, 60 Sterile Ophthalmic Inserts	01/01/2022	33.80	597.13	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208050307	LOTEMAX® (loteprednol etabonate ophthalmic Gel 0.5%), 5g	01/01/2022	12.86	227.16	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208044335	LOTEMAX® (loteprednol etabonate ophthalmic Ointment 0.5%), 3.5g	01/01/2022	18.09	319.64	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208029910	LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 10mL	01/01/2022	32.05	566.20	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208029915	LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 15mL	01/01/2022	47.65	841.79	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208029905	LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 5mL	01/01/2022	16.03	283.13	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208050707	LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38%, 5g	01/01/2022	12.86	227.16	12/23/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208060203	PROLENSA™ (bromfenac ophthalmic solution) 0.07% 3mL	01/01/2022	17.98	317.61	11/11/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208081425	TIMOPTIC-XE® (Timolol Maleate Ophthalmic Gel Forming Solution) 0.25%, 5mL	01/01/2022	13.72	242.51	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208081605	TIMOPTIC-XE® (Timolol Maleate Ophthalmic Gel Forming Solution) 0.50%, 5mL	01/01/2022	15.04	265.75	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208050402	VYZULTA™ (latanoprostene bunod ophthalmic solution) 0.024%, 2.5mL	01/01/2022	12.87	227.25	10/03/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208050405	VYZULTA™ (latanoprostene bunod ophthalmic solution) 0.024%, 5mL	01/01/2022	25.72	454.49	10/03/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208053535	ZIRGAN™ (Ganciclovir Ophthalmic Gel 0.15%), 5mL	01/01/2022	23.68	418.36	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208035810	ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension), 10mL	01/01/2022	33.35	589.31	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208035805	ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension), 5mL	01/01/2022	16.68	294.65	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187581030	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 174mg 30ct	01/01/2022	126.89	1733.16	06/27/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187581130	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 348mg 30ct	01/01/2022	167.28	2284.74	06/27/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187581230	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 522mg 30ct	01/01/2022	380.68	5199.39	06/27/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187006410	ATIVAN® Tablets 1mg 1,000s	01/01/2022	2974.12	40621.20	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187006301	ATIVAN® Tablets .5mg 100s	01/01/2022	227.32	3104.86	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187006401	ATIVAN® Tablets 1mg 100s	01/01/2022	303.68	4147.65	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187006501	ATIVAN® Tablets 2mg 100s	01/01/2022	483.97	6610.05	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187000201	BRYHALI™ (halobetasol propionate) Lotion 0.01%, 100g	01/01/2022	26.97	476.41	11/02/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187000260	BRYHALI™ (halobetasol propionate) Lotion 0.01%, 60g	01/01/2022	16.18	285.84	11/02/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2022	25010030515	DEMSER® (metyrosine), 250mg Capsules, 100ct	01/01/2022	3085.63	42144.28	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187540004	JUBLIA® (efinaconazole) Topical Solution 10%, 4mL	01/01/2022	38.62	682.24	04/25/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187540008	JUBLIA® (efinaconazole) Topical Solution 10%, 8mL	01/01/2022	77.24	1364.48	04/25/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187301220	MESTINON 60mg /SYRUP (pyridostigmine bromide) 473mL 1 Bottle	01/01/2022	110.09	1503.60	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187301030	MESTINON 60mg TABLETS 100s (pyridostigmine bromide)	01/01/2022	135.54	1851.16	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187301330	MESTINON TIMESPAN 180mg TABLETS (pyridostigmine bromide) 30 CT	01/01/2022	77.12	1053.33	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	66490069110	MYSOLINE 250 mg TABLETS, 100s (primidone)	01/01/2022	435.62	5949.85	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	66490069010	MYSOLINE 50 mg TABLETS, 100s (primidone)	01/01/2022	126.59	1728.97	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187305050	ONEXTON™ (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/3.75% 50g Pump	01/01/2022	37.70	665.97	08/05/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187442010	PEPCID® (Famotidine) Tablets, 20mg, 100	01/01/2022	96.82	1322.35	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187442030	PEPCID® (Famotidine) Tablets, 20mg, 30	01/01/2022	29.04	396.71	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187444010	PEPCID® (Famotidine) Tablets, 40mg, 100	01/01/2022	187.14	2555.89	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187444030	PEPCID® (Famotidine) Tablets, 40mg, 30	01/01/2022	56.14	766.72	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187000402	SILIQ™ (brodalumab) Injection 210mg/1.5mL (1 box of 2 syringes)	01/01/2022	389.33	4321.93	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187149825	TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.25%, 0.3mL, 60ct	01/01/2022	28.20	498.17	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187149605	TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.50%, 0.3mL, 60ct	01/01/2022	32.16	568.08	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014090	VASOTEC® 2.5mg Tablets, 90s	01/01/2022	106.29	1451.73	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014210	VASOTEC® 10mg Tablets, 1,000s	01/01/2022	1506.49	20576.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014230	VASOTEC® 10mg Tablets, 30s	01/01/2022	45.19	617.22	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014290	VASOTEC® 10mg Tablets, 90s	01/01/2022	135.60	1852.02	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014030	VASOTEC® 2.5mg Tablets, 30s	01/01/2022	35.43	483.93	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014310	VASOTEC® 20mg Tablets, 1,000s	01/01/2022	2143.54	29276.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014330	VASOTEC® 20mg Tablets, 30s	01/01/2022	64.31	878.37	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014390	VASOTEC® 20mg Tablets, 90s	01/01/2022	192.93	2635.02	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014130	VASOTEC® 5mg Tablets, 30s	01/01/2022	41.10	561.32	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014190	VASOTEC® 5mg Tablets, 90s	01/01/2022	123.27	1683.68	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187073030	WELLBUTRIN® XL 150mg Tablets, 30ct	01/01/2022	125.29	1711.17	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187073090	WELLBUTRIN® XL 150mg Tablets, 90ct	01/01/2022	375.88	5133.82	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187073130	WELLBUTRIN® XL 300mg Tablets, 30ct	01/01/2022	165.38	2258.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187045302	ZELAPAR (selegiline HCI) 1.25mg Orally Disintegrating Tablets, 60ct	01/01/2022	382.93	5230.21	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000024	Bayer	03/31/2022	50419025091	ADEMPAS 0.5 MG TABLET 9 count	01/01/2022	69.66	1231.20	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025001	ADEMPAS 0.5 MG TABLET 90 count	01/01/2022	696.60	12312.00	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025191	ADEMPAS 1 MG TABLET 9 count	01/01/2022	69.66	1231.20	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025101	ADEMPAS 1 MG TABLET 90 count	01/01/2022	696.60	12312.00	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025291	ADEMPAS 1.5 MG TABLET 9 count	01/01/2022	69.66	1231.20	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025201	ADEMPAS 1.5 MG TABLET 90 count	01/01/2022	696.60	12312.00	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025391	ADEMPAS 2 MG TABLET 9 count	01/01/2022	69.66	1231.20	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025301	ADEMPAS 2 MG TABLET 90 count	01/01/2022	696.60	12312.00	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025491	ADEMPAS 2.5 MG TABLET 9 count	01/01/2022	69.66	1231.20	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025401	ADEMPAS 2.5 MG TABLET 90 count	01/01/2022	696.60	12312.00	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	06/30/2022	50419048858	Nexavar 200mg 120 Tablets	05/26/2022	621.60	22814.40	09/10/2028	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	06/30/2022	50419017101	Stivarga 40 mg tab 28 count bottle	05/26/2022	262.08	6817.44	06/02/2030	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	06/30/2022	50419017103	Stivarga 40 mg tab 3x28 count bottle	05/26/2022	786.24	20452.32	06/02/2030	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000483	Benuvia Operations, LLC	12/31/2022	78613020130	Syndros (dronabinol) oral solution, CII 5 mg/mL - 1 Bottle	12/20/2022	583.33	1749.99	08/06/2028	Single Source Drug	None	1	None	1	None	1	08/24/2022	Benuvia, Inc.	None	1	None	1166.66	1166.66	2017	973.00	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=671	None
Rx0000099	Biogen	03/31/2022	64406000801	TYSABRI (natalizumab) Injection 300 mg/15 mL (20 mg/mL) solution in a single-dose vial	01/01/2022	391.85	7855.84	03/05/2027	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Tysabri was not acquired by Biogen from another company in the last 5 years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014130	GILOTRIF 20MG TABLET 30	01/10/2022	403.30	10485.72	07/05/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=622	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597013730	GILOTRIF 30MG TABLET 30	01/10/2022	403.30	10485.72	07/05/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=617	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597013830	GILOTRIF 40MG TABLET 30	01/10/2022	403.30	10485.72	07/05/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=618	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597015230	JARDIANCE 10MG TABLET 30	01/10/2022	21.94	570.48	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=631	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597015237	JARDIANCE 10MG TABLET 3x10	01/10/2022	21.94	570.48	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=632	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597015290	JARDIANCE 10MG TABLET 90	01/10/2022	65.83	1711.44	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=633	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597015330	JARDIANCE 25MG TABLET 30	01/10/2022	21.94	570.48	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=634	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597015337	JARDIANCE 25MG TABLET 3x10	01/10/2022	21.94	570.48	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=635	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597015390	JARDIANCE 25MG TABLET 90	01/10/2022	65.83	1711.44	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=636	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014818	JENTADUETO 2.5MG-1000MG Tablet 180	01/10/2022	58.27	1514.64	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=629	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014860	JENTADUETO 2.5MG-1000MG Tablet 60	01/10/2022	19.42	504.88	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=630	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014618	JENTADUETO 2.5MG-500MG Tablet 180	01/10/2022	58.27	1514.64	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=625	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014660	JENTADUETO 2.5MG-500MG Tablet 60	01/10/2022	19.42	504.88	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=626	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014718	JENTADUETO 2.5MG-850MG Tablet 180	01/10/2022	58.27	1514.64	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=627	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014760	JENTADUETO 2.5MG-850MG Tablet 60	01/10/2022	19.42	504.88	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=628	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597027094	JENTADUETO XR 2.5MG-1000MG Tablet 180	01/10/2022	58.27	1514.64	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=648	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597027073	JENTADUETO XR 2.5MG-1000MG Tablet 60	01/10/2022	19.42	504.88	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=647	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597027533	JENTADUETO XR 5MG-1000MG Tablet 30	01/10/2022	19.42	504.88	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=649	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597027581	JENTADUETO XR 5MG-1000MG Tablet 90	01/10/2022	58.27	1514.64	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=650	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014360	OFEV 100MG CAPSULE 60	01/10/2022	444.54	11558.14	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=623	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	09/30/2022	00597014360	OFEV 100MG CAPSULE 60	07/01/2022	222.28	11780.42	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014560	OFEV 150MG CAPSULE 60	01/10/2022	444.54	11558.14	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=624	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	09/30/2022	00597014560	OFEV 150MG CAPSULE 60	07/01/2022	222.28	11780.42	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597019705	PRAXBIND 2.5g/50mL Vials 2	01/10/2022	171.17	4450.43	07/20/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=646	For Column F, this drug is not listed in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), and there are no patents listed in the FDA database “Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations”. Patent expiration is provided from the Orange Book listing for an associated drug. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597007541	SPIRIVA HANDIHALER 18mcg Blister Card 30	01/10/2022	19.12	497.12	04/19/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=613	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597007575	SPIRIVA HANDIHALER 18mcg Blister Card 5	01/10/2022	3.79	98.46	04/19/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=615	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597007547	SPIRIVA HANDIHALER 18mcg Blister Card 90	01/10/2022	57.35	1491.36	04/19/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=614	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597016061	SPIRIVA RESPIMAT 1.25mcg Cartridge 4	01/10/2022	19.12	497.12	04/16/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=639	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597010061	SPIRIVA RESPIMAT 2.5mcg Cartridge 4	01/10/2022	19.12	497.12	04/16/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=616	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597016818	SYNJARDY 12.5-1000MG Tablet 180	01/10/2022	65.83	1711.44	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=640	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597016860	SYNJARDY 12.5-1000MG Tablet 60	01/10/2022	21.94	570.48	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=641	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597018018	SYNJARDY 12.5-500MG Tablet 180	01/10/2022	65.83	1711.44	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=644	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597018060	SYNJARDY 12.5-500MG Tablet 60	01/10/2022	21.94	570.48	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=645	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597017518	SYNJARDY 5-1000MG Tablet 180	01/10/2022	65.83	1711.44	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=642	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597017560	SYNJARDY 5-1000MG Tablet 60	01/10/2022	21.94	570.48	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=643	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597015918	SYNJARDY 5-500MG TABLET 180	01/10/2022	65.83	1711.44	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=637	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597015960	SYNJARDY 5-500MG TABLET 60	01/10/2022	21.94	570.48	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=638	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597028073	SYNJARDY XR 10mg-1000mg Tablet 30	01/10/2022	21.94	570.48	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=651	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597028090	SYNJARDY XR 10mg-1000mg Tablet 90	01/10/2022	65.83	1711.44	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=652	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597030093	SYNJARDY XR 12.5mg-1000mg Tablet 180	01/10/2022	65.83	1711.44	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=658	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597030045	SYNJARDY XR 12.5mg-1000mg Tablet 60	01/10/2022	21.94	570.48	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=657	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597029588	SYNJARDY XR 25mg-1000mg Tablet 30	01/10/2022	21.94	570.48	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=656	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597029578	SYNJARDY XR 25mg-1000mg Tablet 90	01/10/2022	65.83	1711.44	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=655	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597029059	SYNJARDY XR 5mg-1000mg Tablet 180	01/10/2022	65.83	1711.44	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=653	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597029074	SYNJARDY XR 5mg-1000mg Tablet 60	01/10/2022	21.94	570.48	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=654	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014061	TRADJENTA 5MG TABLET 100	01/10/2022	64.74	1682.93	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=620	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014030	TRADJENTA 5MG TABLET 30	01/10/2022	19.42	504.88	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=619	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014090	TRADJENTA 5MG TABLET 90	01/10/2022	58.27	1514.64	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=621	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000078	Bristol Myers Squibb	03/31/2022	00003089321	ELIQUIS 2.5 MG Tablet, Bottle of 60 Tablets	01/01/2022	29.94	529.01	02/24/2031	Single Source Drug	None	1	"We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply."	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2022	00003089331	ELIQUIS 2.5 MG Tablet, Bottle x 100 Tablets	01/01/2022	49.91	881.76	02/24/2031	Single Source Drug	None	1	"We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply."	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2022	00003089470	ELIQUIS 5 MG Tablet Bottle of 74 Tablets	01/01/2022	36.93	652.46	02/24/2031	Single Source Drug	None	1	"We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply."	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2022	00003376474	ELIQUIS 5 MG Tablet, 74 Tablets (1 blister pack of 42 tabs and 1 blister pack of 32 tabs)	01/01/2022	36.93	652.46	02/24/2031	Single Source Drug	None	1	"We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply."	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2022	00003089421	ELIQUIS 5 MG Tablet, Bottle of 60 Tablets	01/01/2022	29.94	529.01	02/24/2031	Single Source Drug	None	1	"We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply."	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2022	00003089431	ELIQUIS 5 MG Tablet, Hospital Unit-Dose, Blister Package of 100	01/01/2022	49.91	881.76	02/24/2031	Single Source Drug	None	1	"We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply."	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2022	00003218713	ORENCIA 250 MG Intravenous Solution, 1 Vial	07/01/2022	30.52	1301.99	12/19/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years